Mass spectrometry, originally invented by particle physicists at the end of 1890s, has been developed into a unique technology after a century of continuous innovation. Since the two ionization technologies (ESI and MALDI) won the Nobel Prize in 2002, mass spectrometry has leaped out of traditional physical chemistry, leading to rapid advances in the biological field. The complex organism itself and the multivariate research scope of modern biology provide the unquestionable space of technological innovation for the development of mass spectrometry technology. At the same time, it also makes the biology research more thorough and extensive. In recent years, massspectrometry- based omics technologies play vital roles in the discovery of new biological findings, authentic disease biomarkers, as well as complex disease mechanisms. Taking important clinical questions as the root, our research develops cutting-edge high-throughput multi-omics technologies (including single-cell proteomics, absolute quantitative proteomics, glycomics, extracellular vesicleomics, etc.). Through exploring and revealing the unknowns in biomedical and clinical research, we aim at effectively establishing standardized procedures for the development and verification of clinical biomarkers, with ultimate contributions to human health.
